Recent Updates
Recently added Catalysts
DARE Positive Sentiment

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

Thursday, July 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Daré Bioscience's CEO, Sabrina Martucci Johnson, will participate in a virtual investor event on July 14, 2026. The event aims to enhance engagement with investors and showcase the company's commitment to women's health. The live video webcast will begin at 4:00 PM ET.
Price reaction · baseline $2.03 (2026-07-08 close) · hit pre-market · 1 other DARE headline(s) in the window, move may be shared
day 0 close · peak
+2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a virtual investor event highlights company engagement.
  • Focus on women's health indicates a commitment to addressing critical issues.
  • Live webcast provides transparency and accessibility for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1%
120-day peak, hindsight
Typical move
8.6%
average across 2 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
Diclofenac 1%
Phase 1 · Dysmenorrhea Primary

Full Press Release Details

Live video webcast on Tuesday, July 14 th, at 4:00 PM ET Register here SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions,

Frequently Asked Questions

When is the Daré Bioscience investor event?

The investor event is scheduled for July 14, 2026, at 4:00 PM ET.

Who will represent Daré Bioscience at the event?

Sabrina Martucci Johnson, the CEO of Daré Bioscience, will participate.

What is the focus of Daré Bioscience?

Daré Bioscience focuses on closing the gap in women's health.

How can investors join the webcast?

Investors can register for the live video webcast to join the event.

ShareAdd on Google
Tags: DARE Viatris Investor Conferences Healthcare Daré Bioscience Sabrina Martucci Johnson women's health investor event NASDAQ: DARE
Last updated: Jul 9, 2026

Biotech snapshot

Cash runway
$13M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
Diclofenac 1%Phase 1
Dysmenorrhea Primary →

Catalyst track record

+1%
best trade around DARE's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DARE.

See every catalyst's timing & PoA →